First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

Adcendo ApS

Status and phase: Begins enrollment this month; Phase 1

Conditions: Solid Tumors (Phase 1)

Treatments: Drug: ADCE-B05

Study type: Interventional

Funder types: Industry

Identifiers

NCT07362888

ADCE-B05-001

Details and patient eligibility

About

The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.

Full description

Safety and tolerability will be evaluated by incidence of DLTs. Efficacy will be evaluated by antitumor activity: ORR, DOR, PFR, and TTR per RECIST v 1.1

Enrollment: 180 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of solid tumor
• Advanced disease (i.e., unresectable locally advanced or metastatic) and refractory to, intolerant of, or ineligible for approved therapies
• Radiologically or clinically determined progressive disease during or after most recent line of therapy
• Measurable disease per RECIST 1.1
• ECOG performance status of 0 or 1
• Adequate hematological and biochemical parameters
• A male patient must agree to use barrier contraception during the treatment period and for at least 4 months after the last infusion of study treatment, and refrain from donating sperm during this period. Male patients with a pregnant partner must practice sexual abstinence or use a barrier method of contraception (e.g., condom) to prevent exposure of the fetus or neonate
• A female patient who is not pregnant, not breast feeding, and either not a woman of childbearing potential (WOCBP) or agrees to follow the contraceptive guidance during the treatment period and for at least 7 months after last infusion of study treatment

Exclusion Criteria

• Treatment with systemic anticancer therapy, including any investigational agent within 3 weeks or 5 half-lives (whichever is shorter) prior to study treatment administration
• Prior treatment with an ADC containing a topoisomerase I inhibitor payload
• Primary brain malignancy or known, untreated central nervous system (CNS) or leptomeningeal metastases, or symptoms suggesting CNS involvement for which treatment is required
• Other malignancy
• Major surgical procedure or significant traumatic injury within 28 days prior to study drug administration
• Ongoing systemic infection requiring treatment with antibiotics, antivirals, or antimycotics, other than prophylactic treatment
• Persistent toxicities from previous systemic anti-neoplastic treatments of Grade >1
• Clinically significant cardiovascular disease
• Acute infection with human immunodeficiency virus (HIV)-1 or HIV-2
• Current active liver disease due to hepatitis B or hepatitis C
• History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis or pulmonary lymphangitic carcinomatosis

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

180 participants in 1 patient group

ADCE-B05

Experimental group

Description:

Dose escalation followed by a dose expansion phase. ADCE-B05 is administered intravenously on a 3 weekly dosing cycle

Treatment:

Drug: ADCE-B05